Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.
Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...
Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital ...
TPST-1120 is a small molecule commercialized by Tempest Therapeutics, with a leading Phase II program in Metastatic Hepatocellular Carcinoma (HCC).
Casdozokitug is a monoclonal antibody commercialized by Coherus BioSciences, with a leading Phase II program in Hepatocellular Carcinoma.
Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...
The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of ...
Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.
Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had ...
The patient, diagnosed with a large hepatocellular carcinoma in the right lobe of the liver, faced significant challenges due ...
Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the ...
Raveesh Kunwar Malik, a 36-year-old lawyer from Zirakpur, donates his organs saving six lives after a tragic motorcycle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback